Advertisement

Topics

Grünenthal Company Profile

06:46 EST 11th December 2016 | BioPortfolio

Grünenthal è una società farmaceutica indipendente, basata sulla ricerca con operazioni internazionali. E' sempre stata una società a capitale privato fin dalla sua fondazione nel 1946. I prodotti Grünenthal sono commercializzati in oltre 80 Paesi e il numero delle filiali è in continua crescita. Grünenthal occupa circa 4.800 persone a livello mondiale, persone che hanno dato un grande contributo per il successo della Società.L'ulteriore consolidamento attraverso una ricerca innovativa è una parte integrante della politica della nostra Società. L'ambizione di Grünenthal è quella di essere una società leader nella Ricerca e Sviluppo in campi selezionati: l'area dolore è la nostra competenza core.

Location

Via Correggio, 43
Milano
20149
Italy

Contact

Phone: 39-02-43051
Fax: 39-02-430555
Email: dg@grunenthal.com


News Articles [22 Associated News Articles listed on BioPortfolio]

View From The Top: Growing Grünenthal

As he leaves after 23 years at the firm, outgoing CEO Eric-Paul Pâques talks about Grünenthal's growth and strategic priorities...    

Grünenthal makes US acquisition to expand portfolio for CRPS

German family-owned drugmaker Grünenthal has announced its recent acquisition of a USA-based clinical-stage,…

Grünenthal’s cebranopadol meets primary efficacy endpoint in Phase III trial in cancer pain

Grünenthal on Friday presented data for the first time of its compound cebranopadol in patients with…

Grünenthal acquires US-based Thar Pharmaceuticals

Germany-based Grünenthal has acquired US clinical-stage, specialty pharmaceutical firm Thar Pharmaceuticals.

Grünenthal Acquires Thar Pharmaceuticals

The Grünenthal Group has acquired Thar Pharmaceuticals for an undisclosed price, in a deal that adds a late-stage drug candidate to the buyer’s portfolio of pain treatments. The acquisition...

Grünenthal New CEO: My Strategic Priorities

Gabriel Baertschi, the new head of midsize German pharma firm Grünenthal talks to Jo Shorthouse about his first moves as...    

Grünenthal On Hunt For Asia Partner As Pain Killer Hits Phase III Endpoints

Grünenthal’s novel pain killer has succeeded in a Phase III trial in cancer pain and now the company wants to...   

#news #biotech Grünenthal buys Thar to expand late-phase pain pipeline

// Grünenthal buys Thar to expand late-phase pain pipeline nick.paul.taylor Thu, 11/17/2016 – 05:18 from Feed http://ift.tt/2gln6Td Cet article #news #biotech Grünenthal buys Thar to expand la...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [3 Associated Companies listed on BioPortfolio]

Grünenthal

Grünenthal è una società farmaceutica indipendente, basata sulla ricerca con operazioni internazionali. E' sempre stata una società a capitale privato fin dalla sua fondazione nel 1946. I prodotti...

Gr?nenthal

Grünenthal GmbH

Nil

More Information about "Grünenthal" on BioPortfolio

We have published hundreds of Grünenthal news stories on BioPortfolio along with dozens of Grünenthal Clinical Trials and PubMed Articles about Grünenthal for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Grünenthal Companies in our database. You can also find out about relevant Grünenthal Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record